Birden Fazla Sürücü Mutasyonlu Küçük Hücre Olmayan Akciğer Kanserli Hastalarda Optimum Yaklaşım İçin Hangi Tedavi Seçilmelidir? Bir Vaka Raporu ve Literatür İncelemesi-Reference-Cited by-同舟云学术

Birden Fazla Sürücü Mutasyonlu Küçük Hücre Olmayan Akciğer Kanserli Hastalarda Optimum Yaklaşım İçin Hangi Tedavi Seçilmelidir? Bir Vaka Raporu ve Literatür İncelemesi

Published:2022-04-14 Issue: Volume: Page:
ISSN:2687-2781
Container-title:Akdeniz Medical Journal
language:tr
Short-container-title:Akd Tıp D

Author:

BALÇIK Onur Yazdan¹,OKTAY Esin²,DÖNMEZ YALÇIN Gizem²

Affiliation:

1. ADNAN MENDERES UNIVERSITY

2. AYDIN ADNAN MENDERES UNIVERSITY

Abstract

We present a case of concomitant c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) and fusion in non small cell lung cancer (NSCLC) in a 59-year-old patient and review the treatment efficacy of co-mutations. The choice of the treatment and its effectiveness with rare co-mutations is a subject of considerable interest. This review will provide clues to the optimal treatment approach to NSCLC patients with more than one driver mutations. However, randomized studies are needed to clarify which patients with concurrent mutations may benefit from chemotherapy or related tki.

Publisher

Akdeniz University

Reference23 articles.

1. 1. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011;12(8):735-742.

2. 2. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010;11(2):121-128.

3. 3. Mok TS, Wu Y, Thongprasert S, Yang, C, Chu D, Saijo N, Sunpaweravong P, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine, 2009;361(10): 947-957.

4. 4. Zhang X, Zhang S, Yang Z, Yang J, Zhou Q, Yin Y, An S. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer, 2010;9(1):1-12.

5. 5. An SJ, Chen ZH, Su J, Zhang WZ, Zhong WZ, Yang JL, Zhou Q. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One, 2012;7(6): e40109.